Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

Clin Infect Dis. 2008 Feb 15;46(4):577-83. doi: 10.1086/526772.


The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Clinical studies comparing linezolid with 2 doses of dalbavancin have shown comparable efficacy for the treatment of skin and soft-tissue infection. Dalbavancin has also proven to be effective for therapy of catheter-related bloodstream infections. It has an excellent safety profile in studies to date. Dalbavancin will likely have a significant role in outpatient intravenous therapy for patients with potentially serious drug-resistant gram-positive coccal infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / drug therapy
  • Gram-Positive Bacterial Infections / drug therapy*
  • Half-Life
  • Humans
  • Skin Diseases, Bacterial / drug therapy
  • Soft Tissue Infections / drug therapy
  • Teicoplanin / adverse effects
  • Teicoplanin / analogs & derivatives*
  • Teicoplanin / pharmacokinetics
  • Teicoplanin / pharmacology


  • Anti-Bacterial Agents
  • Teicoplanin
  • dalbavancin